Today, FOFWEEKLY officially released its 2026 Investment Institution Soft Power Ranking, and Efung Capital was honored with the Healthcare TOP30 award.
In 2026, the equity investment industry finds itself at a critical intersection of "divergence" and "reconstruction." The market has moved past the initial phase of structural recovery and has formally entered a new cycle where legacy holdings coexist with the pursuit of new growth opportunities. Driven by sustained policy guidance and the commercial deployment of hard technologies, the global competitiveness of Chinese enterprises is shifting from "technological breakthroughs" to the validation of "complete business models." As global competition in the tech sector intensifies, the industrial ecosystems and capital landscapes in which investment institutions operate are undergoing unprecedented reshaping.
Against this backdrop, the "soft power" of investment institutions – encompassing industrial resource integration capabilities, LP relationship management, brand trust, and ecosystem enablement – has evolved from a "differentiator" to a "necessity for survival." It has become a critical lever for navigating market volatility and building a durable long-term competitive advantage.
FOFWEEKLY, drawing on a comprehensive survey of China's equity investment landscape, focuses on value-creation entities with demonstrated capacity for continuous evolution in the new economic cycle. Leveraging its proprietary soft power evaluation model, and strictly adhering to the principles of "fairness, justice, and openness" alongside a balanced quantitative-qualitative assessment framework, the organization conducted a secondary calibration and evaluation of leading institutions.
This year's Soft Power Ranking also featured five specialized sectors – Artificial Intelligence, Aerospace, Healthcare, Hard Technology, and New Economy (including Consumer & Entertainment) – with differentiated research and evaluations conducted to identify outstanding and leading institutions in each domain.
Looking ahead, Efung Capital will continue to deepen public-private collaboration and industry-research integration. Amid the new cycle, we will remain anchored in professionalism and propelled by empowerment, injecting sustained momentum into the high-quality development of China's life sciences ecosystem.
Disclaimer: This article reflects the views of Efung Capital based on currently available public information and materials provided by portfolio companies. It does not constitute investment advice, medical advice, or a guarantee of any company's performance. Investment involves risk; please exercise caution and make independent judgments based on public information. Reproduction or commercial use without authorization is prohibited.